POP-Brazil study protocol : a nationwide cross-sectional evaluation of the prevalence and genotype distribution on human papillomavirus (HPV) in Brazil by Wendland, Eliana Marcia da Ros et al.
1Wendland EM, et al. BMJ Open 2018;8:e021170. doi:10.1136/bmjopen-2017-021170
Open Access 
POP-Brazil study protocol: a nationwide 
cross-sectional evaluation of the 
prevalence and genotype distribution of 
human papillomavirus (HPV) in Brazil
Eliana Marcia Wendland,1,2 Juliana Caierão,1 Carla Domingues,3 
Ana Goretti Kalume Maranhão,3 Flávia Moreno Alves de Souza,4 
Luciano Serpa Hammes,1 Maicon Falavigna,1,5 Juliana Balbinot Hilgert,6 
Fernando Neves Hugo,6 Marina Bessel,1 Luisa Lina Villa,7 
Adele Schwartz Benzaken4
To cite: Wendland EM, 
Caierão J, Domingues C, et al.  
POP-Brazil study protocol: a 
nationwide cross-sectional 
evaluation of the prevalence 
and genotype distribution 
of human papillomavirus 
(HPV) in Brazil. BMJ Open 
2018;8:e021170. doi:10.1136/
bmjopen-2017-021170
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
021170).
Received 15 December 2017
Revised 24 April 2018
Accepted 4 May 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr Eliana Marcia Wendland;  
 eliana. wendland@ hmv. org. br
Protocol
AbstrACt
Introduction Human papillomavirus (HPV) is associated 
with the development of genital warts and different types 
of cancer, including virtually all cervical cancers and a 
considerable number of penile, anal and oropharyngeal 
cancers. Data regarding the prevalence of HPV infection 
in Brazil are limited and fragmented. We aim to determine 
HPV prevalence in sexually active women and men aged 
16–25 years and to investigate regional differences in 
virus prevalence and types.
Methods and analysis This is a nationwide, multicentric, 
cross-sectional, prospective study that will include 
participants aged 16–25 years from all Brazilian capital 
cities. Recruitment will occur in primary health units by 
trained health professionals who will be responsible for 
collecting biological samples and interviewing the volunteers. 
After signing informed consent, all participants will answer 
a questionnaire that will collect sociodemographic and 
behavioural data. All samples will be processed in a certified 
central laboratory, and strict quality control will be performed 
by many different procedures, including double data entry, 
training and certification of primary care health professionals 
responsible for data collection, simulation of interviews, and 
auditing and monitoring of visits. The sample size will be 
standardised based on the population distribution of each 
capital using SAS and R statistical software.
Ethics and dissemination The project was approved by 
the research ethics committee of the main institution and 
the corresponding ethics committees of the recruitment 
sites. This will be the first Brazilian nationwide study to 
determine overall HPV prevalence and to examine regional 
differences and social, demographic and behavioural factors 
related to HPV infection. Critical analysis of the study results 
will contribute to epidemiological knowledge and will set a 
baseline for future evaluation of the impact of the National 
HPV Vaccination Program.
IntroduCtIon
According to the WHO, more than 528 000 
incident cases and approximately 270 000 
deaths due to cervical cancer occur annually 
worldwide, 85% of which occur in low-income 
and middle-income countries.1 Virtually all 
these cancers are preceded by infection with 
high-risk oncogenic human papillomaviruses 
(HR-HPVs),2 and HPV types 16 and 18 are 
associated with 70% of these cases.3 4 In Brazil, 
the National Institute of Cancer estimated 
that there were 16 340 new cervical carcinoma 
cases in 2016, with a 33.23% mortality rate.5 
HR-HPVs are also responsible for 63% of 
penile cancers, 89% of anal cancers and 72% 
of oropharyngeal cancers in men.6 7 Indeed, 
these viruses are now recognised as the major 
cause of the observed rising incidence rates 
of oropharyngeal squamous cell carcinoma; 
indeed, the primary risk factor for developing 
this cancer is oral HPV infection.8
Most sexually active individuals will be 
infected by HPV at some point in their lives.9 10 
In Brazil, the prevalence of HPV infection in 
women with normal cervical cytology varies 
from 2.3% to 55.4%.11 12 Considerable vari-
ability in HPV prevalence rates for other body 
sites, such as the penile epithelium and the 
oral cavity, is also observed in Brazil.11 12
strengths and limitations of this study
 ►  Representativeness of all regions of Brazil.
 ► Establishment of a baseline to evaluate the effec-
tiveness of the human  papillomavirus vaccination 
programme in Brazil.
 ► Recruitment done in primary care units, inviting all 
people within the age range living in the area and 
not over-representing risk-factor groups.
 ► Only the population that uses the primary care units 
from the public health system will be included but 
that consists of 71% of the Brazilian population.
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These data originated from studies that were hetero-
geneous with regard to methodology and/or the study 
population. In addition, virtually all studies to date 
were geographically restricted13–17 and/or focused on 
specific groups of individuals, such as HIV-positive, preg-
nant and immunosuppressed patients.18–20 Moreover, 
some of those studies recruited participants from clinics 
specialising in sexually transmitted infections (STIs), 
resulting in selection bias and inflation of the estimated 
prevalence.13–20
Vaccination against HPV is being performed in many 
countries, and it is a method of primary prevention of 
cancer and HPV infection.9 Since 2014, the Brazilian 
Ministry of Health has provided a quadrivalent (types 6, 
11, 16 and 18) vaccine for women aged 9–14 years, with a 
schedule of 0 and 6 months. In January 2017, Brazil was 
the first country in Latin America to extend vaccination 
to men (11–14 years of age).21 Baseline data of HPV prev-
alence before vaccinations are vital in order to establish 
the impact of vaccination on the distribution of HPV 
types.
As far as we know, this is the first study presenting a 
nationwide scope with uniform methodology to evaluate 
the Brazilian prevalence of HPV and its types, as well as 
to compare the prevalence among specific geograph-
ical regions that present marked differences in social, 
demographic, cultural and economic characteristics. In 
addition, the study will describe the social, demographic, 
economic and behavioural factors associated with HPV 
positivity.
objECtIvEs
The primary objective of the study is to determine the 
prevalence of HPV in women and men aged 16–25 years 
in Brazil, evaluating the most prevalent types and possible 
differences between regions and risk factors associated 
with positivity to establish a baseline for evaluation of 
vaccine effectiveness.
secondary objectives
 ► To determine the prevalence of HPV, high-risk types, 
genital warts and the associated sexual behaviours.
 ► To evaluate the coinfection of HPV-HIV in the young 
population that uses the public health system.
 ► To investigate the beliefs and knowledge about HPV 
infection and vaccination in a young population.
 ► To evaluate the association of other STIs, such as syph-
ilis, with the presence of HPV.
 ► To evaluate the herd effect in a sample of unvacci-
nated men.
MEthods And AnAlysIs
design
We will use a cross-sectional, nationwide, multicentric 
design to establish a baseline dataset that will enable prev-
alence comparison over time.
recruitment and sample size
Beginning in January 2017, sexually active women and 
men aged 16–25 years who use the public health system in 
all 26 Brazilian capitals plus the Federal District of Brasilia 
across the five geographical regions will be recruited 
through public primary care units.
Because endocervical collection is not recommended 
during pregnancy in Brazil and/or to avoid selection bias, 
the following exclusion criteria will be applied: pregnant 
women, those who delivered a baby in the last 3 months, 
those who have undergone a hysterectomy or trachelec-
tomy and those who have ever had cervical intraepithelial 
neoplasia grade 2 or higher will be considered ineligible 
for the study.
There will be no exclusion based on HPV vaccination 
status, but we will investigate whether the participants 
have been vaccinated. Since the vaccination programme 
was launched in 2014 for women who were 9–13 years 
of age and our study population is among 16–25 years old, 
we believe that most of the volunteers will be not have 
been vaccinated.
The primary care units in each city were selected based 
on their representativeness of the health districts and based 
on their resources to collect and store oral samples. Most of 
these units have a defined territory and a list of all people 
within the age range. When the list is available, all partici-
pants will be invited. When the list is not available, partici-
pants will be recruited by different approaches: (1) eligible 
individuals who came to the unit for any reason not asso-
ciated with the main study’s outcome, (2) personal invita-
tion by the community health agents and (3) invitation by 
nurses in the school-based health promotion programme. 
The study sample size (7935 individuals) was calculated 
to detect differences of 5% in HPV prevalence between 
regions with a power of 80% and an alpha error of 5% for 
women using an estimate of 30%22 for the prevalence of 
HPV in Brazil. This sample size will allow an estimate with 
an error between 1.6% and 5.7%, according to sex.
The sample size will be purposely equal in all regions 
(1587 individuals) to maximise the diversity in less-popu-
lated areas and will be standardised by the Brazilian popu-
lation of each region during analyses.
Measurements
Sociodemographic variables
Participants will be asked to answer questions regarding 
age, gender, race/skin colour, household characteristics, 
relationship status, educational level, occupational status, 
last-month family income and the number of people 
dependent on this income.
Smoking, alcohol and other drugs
Questions concerning current and past smoking habits, 
including quantity and frequency, will be asked of the 
participants. Moreover, the interview includes questions 
about the use of alcohol and other drugs such as mari-
juana, cocaine, ecstasy, crack and the abuse of morphine 
or other licit and illicit drugs.
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Sexual and reproductive health
Participants will be asked to supply details about their age 
at first sexual intercourse, their involvement in same sex 
relationships, their use of condoms, the number of sexual 
partners, their sexual practices and the presence of any 
genital symptoms during or after sexual intercourse such 
as pain or bleeding.
Their age of menarche, the number of pregnancies and 
deliveries, the number of abortions, their use of contra-
ceptive methods and the occurrence of STIs will be asked 
of participants to evaluate their sexual health. All suspi-
cious HPV-related lesions will be photographed for future 
evaluation.
Knowledge about HPV, vaccination and screening tests
We will measure how much participants know about HPV 
and vaccination (when and who must receive the vaccine). 
The questionnaire is based on Saulle et al.23 Moreover, 
participants will be asked if they know about Pap smears, 
if they have already undergone the examination and if so, 
whether any alteration have ever been observed.
HPV frequency and type
We will measure the proportion of the sample that is 
infected by HPV, and we will look at the prevalence of 
high-risk types and the most prevalent types in the genital 
and oropharyngeal sites. Additionally, we will investigate 
the presence of chronic lesions (lasting 15 days or more) 
in the oral cavity that are related to the presence of HPV.
outcomes
The nationwide prevalence of HPV in the genitals is the 
major outcome. Secondary outcomes include the prev-
alence of specific HPV types, the comparison of preva-
lence between Brazilian regions and the prevalence of 
HR-HPVs and low risk-HPVs.
Procedures
All individuals will respond to a standardised interview 
based on validated instruments.23–26 After the interview, 
samples from the oral cavity and cervical or penile/scrotal 
sites will be collected from each participant.
An online platform for data entry will be used by 
primary care professionals to add participant data, 
biological sample information and photographs. The 
same platform will be used for study process control and 
to allow availability of the results to primary care health 
professionals. Participants will have access to an external 
webpage where they will be able to find information 
about their results, as protected by a password provided 
during interview. In cases in which HR -HPV infection is 
detected, those participants will be asked to return to the 
primary care unit to be informed about the result.
Oral samples will be obtained through mouthwash and 
gargle cycles by using 10 mL of a standardised commer-
cial mouthwash. The samples will be obtained in 3 cycles 
of 5 s each and will be stored in a 15 mL Falcon tube iden-
tified with a five-digit number bar code and the date of 
collection.
Cervical samples will be obtained using the Digene 
HC2 DNA Collection kit (Qiagen) and placed in 1 mL of 
Specimen Transport Medium (STM), according to the 
manufacturer’s instructions.
Penile (penile shaft, glans penis/coronal sulcus) and 
scrotum samples will be obtained using a Dacron swab 
(Qiagen) previously moistened in sterile saline solution. 
Collection will be performed by intensely pressing and 
rubbing the swab in the epithelium via self-collection 
under supervision of the primary care health professional 
and after instruction regarding the procedure.
All biological samples will be maintained at room 
temperature (15°C–25°C) according to manufactur-
er’s instructions and transported to a central labora-
tory in Porto Alegre to start the specimen processing. 
The temperature will be monitored with a data logger. 
Figure 1 presents the general logistics for the nationwide 
multicentre collection of data and specimens.
Individuals who present visible lesions on the genitals 
or in the oral cavity at the time of recruitment will be 
asked to grant permission for a picture to be taken of the 
lesion.
Specimen processing
All samples will be treated as biohazardous material, and 
all specimen handling will be performed in a biosafety 
cabinet. In the laboratory, specimens will be imme-
diately aliquoted. One aliquot will be maintained at 
−80°C as a backup. Another aliquot will be processed for 
DNA extraction from the STM medium using magnetic 
beads for isolation and purification using the automa-
tised extraction platform (MagNA Pure LC V.2.0, Roche 
Molecular Systems), after exposed to an enzymatic treat-
ment with proteinase K, following the manufacturer’s 
instruction.
HPV detection and typing will be done using the Linear 
Array HPV Genotyping Test (Roche Diagnostics) which 
is based on PCR amplification (450 bp fragment of the 
polymorphic region of the L1 gene of HPV), followed 
by specific hybridisation and colorimetric detection, 
according to the manufacturer’s instructions. The test 
detects HR-HPVs (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59 and 68) and LR-HPVs (6, 11, 26, 40, 42, 53, 54, 
55, 61, 62, 64, 66, 67, 69, 70, 71 72, 73, 81, 82, 83, 84, 
IS39 and CP6198), for a total of 37 types. The amplifica-
tion of human β-globin (biotinylated primers GH20 and 
PC04, 268 bp fragment) is used as an internal control for 
the PCR. To ensure reproducibility of LA, an automated 
AutoBlot instrument (Fujirebio) was used for hybridisa-
tion and wash steps. Real-time PCR using the TaqMan 
system for HPV type 52 will be performed to confirm the 
results obtained by Roche’s test as a combination of HPV 
types 52, 33, 35 and 58.
data analyses and statistics
Categorical variables will be summarised using absolute 
frequencies and percentage, while continuous variables 
will be analysed using means and SE. χ2 tests and Fisher’s 
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exact tests will be used to compare proportions, and 
t-tests or Mann-Whitney non-parametric tests will be used 
for continuous variables.
The association between HPV infection and social 
and behavioural variables will be defined by calculating 
crude and adjusted prevalence ratios. Confounding vari-
ables will be evaluated using modified Poisson regression 
analysis.27
To maximise diversity across regions, we have divided 
the sample size into equal numbers among regions. To 
adjust the distribution of the sample to the study popu-
lation, we will standardise the measures by the size of the 
population in each capital within the age range and by 
sex.
Monitoring and quality control
The data quality will be validated by routine practices. A 
pilot study was performed to identify and correct prob-
lems in data collection, sample transportation, proce-
dures and instruments. All health professionals involved 
in the research are trained and certified by the coordi-
nator team using simulated interview and sample collec-
tion according to the study protocol, as described in the 
POP-Brazil operations manuals.
Data and specimen collection are periodically evaluated 
by reports generated by the data system, including infor-
mation about the number of participants and the number 
of refusals, and the quality of the samples collected. Those 
reports will be distributed monthly to all people involved 
in data collection.
Moreover, each unit will receive at least one in loco 
monitoring visit which will be done by research staff 
supervisors to evaluate protocol compliance and provide 
recertification. Supervisors will observe techniques using 
predefined check lists and recorded interviews.
The biological sample tracking is done through the 
web-based data platform, and time, temperature and 
sample conditions are evaluated on a daily basis.
To access the reliability of the interviews, a subsample 
will be obtained in duplicate. A resampling will be done in 
10% of the interviews using phone calls to access the coef-
ficient of variation and systematic differences between 
data. Figure 2 presents the steps that will be taken for 
quality assurance. The reliability of HPV detection will 
be accessed by double processing a random subsample of 
the biological genital samples by the Centers for Disease 
Control and Prevention.
Patient and public involvement
Patients and public were not involved in the study design 
and/or protocol. In cases of no infection or infection 
with a low-risk HPV type, participants will be informed 
of negative results via web access. Conversely, participants 
infected with high-risk HPV types will be advised to go to 
the healthcare unit for their results, where they will be 
oriented about the meaning of the result and instructed 
about follow-up according to national guidelines.
Participants will be informed about the study results 
through study website.
dIsCussIon
This is the first Brazilian nationwide study to deter-
mine HPV prevalence and the social, demographic and 
behavioural factors related to HPV infection. Critical 
analysis of the study results will contribute to epidemio-
logical knowledge of the distribution of HPV strains across 
geographical regions and will establish a baseline to eval-
uate the impact of the Brazilian Vaccination Program.
Figure 1 Workflow of the study. (1) Data are collected in 
public health units from all 27 Brazilian capitals; (2) data entry 
into the web-based system is performed by primary care 
professionals and is monitored by the main research team 
in Porto Alegre (Hospital Moinhos de Vento); (3) paper forms 
are sent to Porto Alegre along with biological samples which 
are processed for DNA extraction Universidade Federal 
de Ciências da Saúde de Porto Alegre (UFCSPA) and (4) 
extracted DNA is sent to Universidade de São Paulo (USP) 
for HPV detection and typing. Finally, the results are included 
in the web-based system and are made available for the 
primary care professionals and participants using a code 
number and password. HPV, human papillomavirus.
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There are some limitations to this study. The sampling 
is not random. Brazil is a large country, and due to logistic 
reasons, the sampling is restricted to state capitals in 
public health units selected by the local government. To 
minimise selection bias, in addition to recruiting partic-
ipants who voluntarily come to the health unit, we will 
also recruit at schools, through the list of patients of 
the selected health units and by personal invitation by 
community health agents in households. We are also only 
recruiting participants in the public health system, who 
account for approximately 70% of the overall Brazilian 
population; therefore, we cannot draw inferences about 
people who exclusively use the private sector. In Brazil, 
the private sector is mainly used by social classes A and B, 
but it is important to highlight that for some services such 
as vaccination, the Public Health System covers virtually 
100% of the population.
The strengths of the study are the establishment of a 
baseline for future comparison of HPV prevalence, the 
nationwide sampling, including a large and diverse popu-
lation and the use of central laboratory and techniques for 
data quality monitoring. Additionally, we will collect data 
on sexual behaviours and other STIs, making it possible 
to pursue some explanation regarding differences in 
prevalence according to specific groups of participants.
Health managers, based on these data, will be able to 
compare HPV prevalence in different regions according 
to population characteristics. It will be possible to support 
the development of strategies to promote HPV vaccina-
tion and to develop strategies for prevention, taking 
into account regional differences. Moreover, these data 
will serve as a baseline for future comparisons and will 
allow monitoring of the effectiveness of the National HPV 
Vaccination Program.
EthICs And dIssEMInAtIon
Before starting the study, this project was submitted to 
the research ethical committee of the proposing institu-
tion (Hospital Moinhos de Vento). Following approval, 
agreements were made by all coparticipant centres and 
submitted to their corresponding ethical committees.
Individuals must voluntarily agree to participate and must 
sign the free and informed consent form. The study follows 
the ethical recommendations of Resolutions 347/05, 
441/11 and 466/12 of the National Health Council.
Preliminary results will be presented as poster and/or 
oral sections in national and international congresses, 
and the final results will be submitted for publishing in 
peer-reviewed open-access journals. The results will also 
be presented in a personal meeting to the Ministry of 
Health of Brazil.
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